US Bancorp’s NovoCure NVCR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $14.5K | Sell |
1,333
-577
| -30% | -$7.21K | ﹤0.01% | 3227 |
|
|
2025
Q4 | $24.7K | Sell |
1,910
-1,018
| -35% | -$13.1K | ﹤0.01% | 2998 |
|
|
2025
Q3 | $37.8K | Sell |
2,928
-2,895
| -50% | -$38.7K | ﹤0.01% | 2799 |
|
|
2025
Q2 | $104K | Sell |
5,823
-152
| -3% | -$2.65K | ﹤0.01% | 2403 |
|
|
2025
Q1 | $106K | Sell |
5,975
-126
| -2% | -$2.86K | ﹤0.01% | 2367 |
|
|
2024
Q4 | $182K | Buy |
6,101
+344
| +6% | +$7.28K | ﹤0.01% | 2069 |
|
|
2024
Q3 | $90K | Sell |
5,757
-1,246
| -18% | -$22.6K | ﹤0.01% | 2446 |
|
|
2024
Q2 | $120K | Buy |
7,003
+2,466
| +54% | +$43.4K | ﹤0.01% | 2252 |
|
|
2024
Q1 | $70.9K | Buy |
4,537
+800
| +21% | +$11.8K | ﹤0.01% | 2525 |
|
|
2023
Q4 | $55.8K | Buy |
3,737
+1,179
| +46% | +$15.8K | ﹤0.01% | 2618 |
|
|
2023
Q3 | $41.3K | Buy |
2,558
+1,176
| +85% | +$33.9K | ﹤0.01% | 2542 |
|
|
2023
Q2 | $57.4K | Sell |
1,382
-123
| -8% | -$7.64K | ﹤0.01% | 2441 |
|
|
2023
Q1 | $90.5K | Buy |
1,505
+139
| +10% | +$11.1K | ﹤0.01% | 2238 |
|
|
2022
Q4 | $100K | Sell |
1,366
-1,218
| -47% | -$91.6K | ﹤0.01% | 2189 |
|
|
2022
Q3 | $197K | Sell |
2,584
-70
| -3% | -$5.46K | ﹤0.01% | 1860 |
|
|
2022
Q2 | $185K | Sell |
2,654
-203
| -7% | -$15.3K | ﹤0.01% | 1921 |
|
|
2022
Q1 | $237K | Buy |
2,857
+454
| +19% | +$33.4K | ﹤0.01% | 1874 |
|
|
2021
Q4 | $180K | Buy |
2,403
+166
| +7% | +$16.7K | ﹤0.01% | 2017 |
|
|
2021
Q3 | $260K | Sell |
2,237
-1,071
| -32% | -$162K | ﹤0.01% | 1847 |
|
|
2021
Q2 | $734K | Buy |
3,308
+430
| +15% | +$83.6K | ﹤0.01% | 1362 |
|
|
2021
Q1 | $381K | Buy |
2,878
+122
| +4% | +$19.3K | ﹤0.01% | 1629 |
|
|
2020
Q4 | $476K | Sell |
2,756
-6,496
| -70% | -$889K | ﹤0.01% | 1462 |
|
|
2020
Q3 | $1.03M | Sell |
9,252
-14
| -0.2% | -$1.12K | ﹤0.01% | 979 |
|
|
2020
Q2 | $549K | Sell |
9,266
-1,008
| -10% | -$66.3K | ﹤0.01% | 1237 |
|
|
2020
Q1 | $692K | Sell |
10,274
-337
| -3% | -$26.6K | ﹤0.01% | 1049 |
|
|
2019
Q4 | $894K | Sell |
10,611
-300
| -3% | -$24.2K | ﹤0.01% | 1100 |
|
|
2019
Q3 | $816K | Sell |
10,911
-2,089
| -16% | -$167K | ﹤0.01% | 1130 |
|
|
2019
Q2 | $822K | Sell |
13,000
-500
| -4% | -$25.3K | ﹤0.01% | 1160 |
|
|
2019
Q1 | $650K | Hold |
13,500
| – | – | ﹤0.01% | 1263 |
|
|
2018
Q4 | $452K | Buy |
13,500
+500
| +4% | +$18.3K | ﹤0.01% | 1385 |
|
|
2018
Q3 | $681K | Hold |
13,000
| – | – | ﹤0.01% | 1306 |
|
|
2018
Q2 | $407K | Hold |
13,000
| – | – | ﹤0.01% | 1532 |
|
|
2018
Q1 | $283K | Hold |
13,000
| – | – | ﹤0.01% | 1691 |
|
|
2017
Q4 | $263K | Hold |
13,000
| – | – | ﹤0.01% | 1732 |
|
|
2017
Q3 | $258K | Buy |
13,000
+3,000
| +30% | +$59K | ﹤0.01% | 1739 |
|
|
2017
Q2 | $173K | Hold |
10,000
| – | – | ﹤0.01% | 1916 |
|
|
2017
Q1 | $81K | Hold |
10,000
| – | – | ﹤0.01% | 2248 |
|
|
2016
Q4 | $79K | Buy |
+10,000
| New | +$80.4K | ﹤0.01% | 2217 |
|
Other funds holding NVCR
SCM
VPM
VCM
QCM
US Bancorp's NVCR Position: Q1 2026 in Review
US Bancorp reduced its NovoCure (NVCR) stake by 30% in Q1 2026, selling an estimated $7.21K and leaving 1,333 shares worth $14.5K. The position accounts for ﹤0.01% of the portfolio, ranked #3227.
US Bancorp first reported a position in NVCR in Q4 2016 and has held it in 38 quarters since. The position peaked at $1.03M in Q3 2020. 222 funds tracked by Wall St. Rank hold NVCR as of Q1 2026.
- US Bancorp held 1,333 shares of NovoCure worth $14.5K as of Q1 2026.
- US Bancorp sold 577 NovoCure shares in Q1 2026, an estimated $7.21K.
- NovoCure made up ﹤0.01% of US Bancorp's portfolio in Q1 2026, its #3227 holding.
- US Bancorp first reported a position in NovoCure in Q4 2016 and has held it in 38 quarters since.
- US Bancorp's NovoCure position peaked at $1.03M in Q3 2020.
- 222 funds tracked by Wall St. Rank held NovoCure as of Q1 2026.
Based on US Bancorp's 13F filing for Q1 2026, filed 15 May 2026.